PhysicianWealth / Certification Series / Pain Management

Ask an anesthesiology resident whether the pain fellowship is worth a year of their life and you'll increasingly get a no: anesthesiology applications to pain fellowships have collapsed 70% between 2019 and 2024. Ask a PM&R resident and you'll get an emphatic yes: their applications are up 68% over the same window (NRMP 2025 match data). Both groups are reading the same market correctly.

Here is the structural fact most ROI write-ups miss. Pain medicine pays roughly the same no matter where you started: a median of $526,445 for anesthesia-trained pain physicians and $501,512 for everyone else (MGMA 2025). But the specialties feeding into it pay wildly different amounts. Anesthesiology already pays $523,277 without any fellowship (Doximity 2025). PM&R pays $374,886. Neurology pays $363,411. The destination is fixed; the starting point determines the return.

This article runs the ROI separately for each entry path -- the averaged-together analyses get this exactly wrong -- then covers the procedural unit economics, the shifting match landscape, and the administrative tax that never shows up in a salary survey. For the same framework applied to every subspecialty, see our fellowship break-even analysis.

The One-Year Fellowship

Pain medicine is a one-year, ACGME-accredited fellowship open to graduates of four residencies: anesthesiology, physical medicine and rehabilitation, neurology, and psychiatry. It is one of the few subspecialty doors that four different specialties can walk through, and the only major one where the training cost is a single year.

The clinical core is interventional: fluoroscopy-guided epidural steroid injections, medial branch blocks and radiofrequency ablation, spinal cord stimulator trials and implants, and an expanding menu of minimally invasive spine procedures. Around the procedures sits the cognitive work -- multidisciplinary chronic pain management, opioid stewardship, cancer pain, and the documentation discipline that the specialty's regulatory environment demands. Graduates sit for the pain medicine subspecialty board exam recognized across the parent boards.

The direct cost of the year is easy to compute. A pain fellow is typically a PGY-5, and the AAMC's 2025 stipend survey puts PGY-5 pay at $81,807. Whatever your specialty would have paid you as a first-year attending, subtract $81,807: that difference is the real price of admission, and it varies enormously by specialty. For an anesthesiologist the fellowship is a $441,470 year. For a neurologist it is a $281,604 year.

The Salary Data Problem

Before the math, an honest disclosure, because pain medicine has a measurement problem that most fellowship ROI articles quietly ignore: the two most-cited physician salary surveys do not track it as a standalone specialty. Doximity's 2025 compensation report and Medscape's 2026 report -- the sources everyone quotes -- fold pain physicians into anesthesiology, PM&R, or neurology. If you have struggled to find a clean "pain management salary" number, that is why.

So this analysis is built on the sources that do isolate it:

For the base specialties we use Doximity 2025 ($523,277 anesthesiology, $374,886 PM&R, $363,411 neurology), cross-checked against Medscape 2026 ($543,000 anesthesiology, $359,000 PM&R). Note the spread between MGMA's $526K and SalaryDr's $630K: MGMA over-samples large employed groups, while SalaryDr's 26 self-reports likely over-sample private-practice owners who are proud of their numbers. The truth for any individual depends on practice model, which is the entire second half of this article.

ROI by Entry Path: The Core Calculation

The formula is identical for everyone. Opportunity cost equals one year of forgone attending salary minus the $81,807 fellow stipend. Annual premium equals the pain medicine median minus your specialty's median. Break-even equals cost divided by premium. What changes -- dramatically -- is the inputs.

Path 1: Anesthesiology -- the surprising non-payoff

Read that again. Using MGMA 2025 pain data against Doximity 2025 anesthesiology data, the anesthesia-trained pain physician earns $3,168 more per year than the colleague who skipped fellowship -- against a $441,470 opportunity cost. Use Medscape's 2026 anesthesiology figure of $543,000 instead and the premium turns negative. On employed salary alone, the anesthesiologist's pain fellowship never breaks even.

This is not a knock on the fellowship; it is a statement about how expensive anesthesiology's status quo has become. Anesthesiology compensation has surged past $520K-$540K, and the old six-figure pain premium evaporated underneath it. The anesthesiologist's case for pain now rests on three things salary medians cannot capture: private-practice procedural economics, clinic-hours lifestyle versus OR call, and long-term practice autonomy. More on each below.

Path 2: PM&R -- the clear financial winner

For a physiatrist, the identical fellowship is a wealth-building machine. The opportunity cost is $148,391 lower than the anesthesiologist's, and the annual payoff is roughly 40 times larger. Break-even arrives about 2.3 years into practice. Over the first decade the cumulative pre-tax surplus is roughly $973,000 ($126,626 × 10, minus the $293,079 opportunity cost) -- before counting any investment returns on the difference.

PM&R residents have done this arithmetic, which is why they are now the fastest-growing applicant pool in the pain match: up 68% from 2019 to 2024 (NRMP 2025).

Path 3: Neurology -- the fastest break-even

Neurology has the lowest base salary of the three main feeder specialties (Doximity 2025: $363,411), which makes its pain ROI the fastest in this analysis: break-even in almost exactly two years and a 10-year pre-tax surplus around $1.1 million. The catch is procedural preparation. Neurology residencies vary widely in fluoroscopy and interventional exposure, so neurologist applicants often need to work harder to demonstrate procedural aptitude. The financial argument, however, is unambiguous.

The side-by-side

*On employed salary medians alone. Private-practice procedural volume changes the anesthesiology math substantially -- see the next two sections.

The Procedure Revenue Engine

Salary medians describe employed physicians. The pain physicians who out-earn every number above do it by owning the procedural revenue, and the unit economics are set each year by the CMS Physician Fee Schedule. The 2026 rates for the specialty's bread-and-butter procedures:

The column that matters is the spread. When a procedure happens in a hospital or ASC, the physician bills the lower facility rate and the institution captures the site fee. In an office-based suite, the practice bills the non-facility rate -- roughly 2.5 to 3x higher for injections and 6.4x higher for stimulator trials ($2,408 vs $378, CMS 2026) -- because the practice absorbs the equipment, staff, and supply costs. Owning the site of service is the single biggest financial lever in pain medicine.

Volume does the rest. A conservative office-based week of 25 epidurals, 15 medial branch blocks, and 8 RFAs collects roughly $14,000 at Medicare non-facility rates -- about $640,000 across a 46-week year, before a single stimulator case, and before commercial payers, which typically reimburse above Medicare. Overhead on an office-based fluoroscopy suite is substantial, but this engine is what produces the private-practice incomes MGMA's employed medians never show, and it is the only version of the fellowship that clearly pays for an anesthesiologist.

The Match Landscape Is Shifting Under Your Feet

The ROI table above is not just theory. It is visible in application behavior, and it has quietly rewritten the competitive landscape of the fellowship itself.

Per NRMP 2025 match data, anesthesiology applicants to pain fellowships fell from 351 in 2019 to 106 in 2024 -- a 70% collapse. Anesthesiologists responded rationally to their own soaring base pay: why surrender $441,470 for a $3,168 raise? Over the same window, PM&R applicants rose from 101 to 170, up 68%, chasing their 2.3-year break-even. The overall position fill rate now sits at 85.4%, meaning roughly one in seven pain fellowship positions goes unfilled.

If you are PM&R or neurology: this is the most favorable pain match in a decade. Programs that once defaulted to anesthesiology applicants are actively recruiting physiatrists and neurologists, and an 85.4% fill rate means strong candidates from less famous residencies are matching at programs that were reaches five years ago.

If you are anesthesiology: the collapse in your own cohort's applications means the fellowship is easier to obtain than at any point in recent memory -- worth knowing if your goal is the private-practice ownership path where the economics still work.

If you are evaluating the specialty's future: a persistently under-filled match feeding a growing chronic pain population is a supply constraint, and supply constraints protect compensation. The shrinking applicant pool is, perversely, bullish for those who enter now.

The Prior Auth Tax

One line item belongs in every pain ROI model and appears in no salary survey: administrative burden. The AMA's 2025 prior authorization survey reports that physicians now average 40 prior auth requests per physician per week, consuming 13 hours of physician and staff time. Interventional pain sits at the heavy end of that distribution, because nearly everything in the CMS table above requires authorization -- repeat epidurals, RFA series, and especially neuromodulation.

Thirteen hours is more than a full clinic day per week. In a specialty whose economics run on procedural throughput, prior authorization is a direct revenue governor: every delayed or denied RFA is $459-$465 of non-facility revenue (CMS 2026) that arrives months late or never. Practices hire dedicated auth coordinators, and that payroll comes out of the same margin the non-facility rates create. Budget for it now -- it is the least advertised feature of the specialty and the most commonly cited frustration of practicing pain physicians.

Private Practice vs Employment: Two Different Careers

By now the pattern should be obvious: every pain medicine number splits into two distributions depending on practice model.

The decision rule falls straight out of the entry-path math. For PM&R and neurology graduates, the fellowship is financially positive in either setting: the $126,626-$138,101 employed premium already justifies the year, and ownership is pure upside. For anesthesiology graduates, employment makes the fellowship a financial wash. The only coherent version of the anesthesia-to-pain path runs through office-based practice or ASC equity, where epidurals bill at $266-$278 instead of $90-$100 and stimulator trials at $2,408 instead of $378.

One honest caveat cuts the other way: CMS has repeatedly trimmed pain procedure reimbursement over the years, and a revenue model concentrated in a handful of CPT codes is exposed to a single payer's pen. Employed physicians are partially insulated from that risk. Owners are not.

The Non-Financial Case

Three things justify the fellowship even where the spreadsheet is ambivalent.

Demand is structural. Chronic pain is among the most common reasons American adults see a physician, the population is aging into more of it, and the opioid crisis permanently redirected referrals toward exactly what this fellowship teaches: procedural, non-opioid pain management. An 85.4%-filled match feeding an expanding patient base is about as protected as physician labor economics gets.

The work is genuinely different. For anesthesiologists, pain trades windowless ORs, nights, and holiday call for clinic hours, longitudinal patient relationships, and a procedure suite you control. For physiatrists and neurologists, it adds a procedural dimension to specialties that are otherwise largely cognitive. Physicians consistently underprice schedule autonomy until they have it.

It is a durable exit option. A pain-boarded anesthesiologist can return to the OR; a pain-boarded physiatrist retains a rehab practice. The fellowship adds a career mode rather than replacing one -- optionality that one-year investments rarely buy.

Against all that, weigh the honest negatives: the prior auth grind (13 hours per week, AMA 2025), the regulatory scrutiny that surrounds any opioid-adjacent specialty, and compensation that depends on sustained procedural volume from your own hands, eyes, and lumbar spine.

Frequently Asked Questions

© 2026 PhysicianWealth. For informational purposes only. Individual compensation varies by geography, practice setting, and negotiation.